ATTN LogoMenu
4UTHRTier 5
기사 목록

UNITED THERAPEUTICS Corp 4

0001231427-26-000003

View on SEC EDGAR

Insider Christopher Patusky received 650 shares of United Therapeutics Corp common stock upon vesting of restricted stock units, increasing his direct holdings to 2,140 shares.

On July 9, 2026, United Therapeutics Corp insider Christopher Patusky had 650 restricted stock units vest and convert on a one-for-one basis into 650 shares of common stock at a stated price of $0.00, reflecting routine equity compensation rather than an open-market transaction. Following this vesting and share issuance (coded as an “M” transaction and an acquisition “A” in the Form 4), Patusky directly owned 2,140 shares of United Therapeutics common stock, while an additional 1,100 shares were held indirectly in a trust. Based on the zero-price reporting convention for RSU vesting, the total dollar value of this grant cannot be calculated from the filing alone, but the transaction represents standard compensation-related share delivery with no concurrent sale reported.

Filing Facts

CIK
1082554
Ticker
UTHR
Form
4
Source Type
fda
Accession
0001231427-26-000003
Alert Tier
5
UNITED THERAPEUTICS Corp 4 | ATTN